References to Yamasa SP-D Kit EIA II - Human Surfactant Protein D ELISA

Yamasa SP-D Kit EIA II - Human Surfactant Protein D ELISA Product Citations

Yamasa SP-D Kit EIA II, developed and manufactured in Japan by Yamasa Corporation, and distributed by Ilex Life Sciences, has been widely referenced in scientific literature. Below you will find some of the scientific papers that reference Yamasa SP-D Kit EIA II.

For more information, please visit the Yamasa SP-D Kit EIA II Product Page.

Arakawa, Noriaki et al. “Serum stratifin and presepsin as candidate biomarkers for early detection of COVID-19 disease progression.” Journal of pharmacological sciences vol. 150,1 (2022): 21-30. doi:10.1016/j.jphs.2022.06.002

Oka, Shomi et al. “Serum rheumatoid factor IgA, anti-citrullinated peptide antibodies with secretory components, and anti-carbamylated protein antibodies associate with interstitial lung disease in rheumatoid arthritis.” BMC musculoskeletal disorders vol. 23,1 46. 13 Jan. 2022, doi:10.1186/s12891-021-04985-0

Yamashita, Masahiro et al. “S100A9/CD163 expression profiles in classical monocytes as biomarkers to discriminate idiopathic pulmonary fibrosis from idiopathic nonspecific interstitial pneumonia.” Scientific reports vol. 11,1 12135. 9 Jun. 2021, doi:10.1038/s41598-021-91407-9

Hirose, Masaki et al. “B cell-activating factors in autoimmune pulmonary alveolar proteinosis.” Orphanet journal of rare diseases vol. 16,1 115. 2 Mar. 2021, doi:10.1186/s13023-021-01755-y

Furukawa, Hiroshi et al. “Serum Metabolomic Profiling in Rheumatoid Arthritis Patients With Interstitial Lung Disease: A Case-Control Study.” Frontiers in medicine vol. 7 599794. 17 Dec. 2020, doi:10.3389/fmed.2020.599794

Ikeda, Kimiyuki et al. “Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.” Respiratory research vol. 21,1 316. 30 Nov. 2020, doi:10.1186/s12931-020-01582-y

Katayama, Kanako et al. “Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis.” Orphanet journal of rare diseases vol. 15,1 272. 29 Sep. 2020, doi:10.1186/s13023-020-01546-x

Ward, Shan L et al. “Association of patient weight status with plasma surfactant protein D, a biomarker of alveolar epithelial injury, in children with acute respiratory failure.” Pediatric pulmonology vol. 55,10 (2020): 2730-2736. doi:10.1002/ppul.24990

Arai, Toru et al. “Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study.” Journal of thoracic disease vol. 12,8 (2020): 4132-4147. doi:10.21037/jtd-20-911

Dahmer, Mary K et al. “Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure.” Chest vol. 158,3 (2020): 1027-1035. doi:10.1016/j.chest.2020.03.041

Nouno, Takashi et al. “Elevation of pulmonary CD163⁺ and CD204⁺ macrophages is associated with the clinical course of idiopathic pulmonary fibrosis patients.” Journal of thoracic disease vol. 11,9 (2019): 4005-4017. doi:10.21037/jtd.2019.09.03

Koyama, Kansuke et al. “Biomarker profiles of coagulopathy and alveolar epithelial injury in acute respiratory distress syndrome with idiopathic/immune-related disease or common direct risk factors.” Critical care (London, England) vol. 23,1 283. 19 Aug. 2019, doi:10.1186/s13054-019-2559-6

Sugino, Keishi et al. “The role of video-assisted thoracoscopic surgery in the diagnosis of interstitial lung disease.” Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG vol. 36,2 (2019): 148-156. doi:10.36141/svdld.v36i2.7797

Combes, Adrien et al. “Continuous exercise induces airway epithelium damage while a matched-intensity and volume intermittent exercise does not.” Respiratory research vol. 20,1 12. 17 Jan. 2019, doi:10.1186/s12931-019-0978-1

Sugino, Keishi et al. “Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis.” Journal of thoracic disease vol. 10,2 (2018): 899-908. doi:10.21037/jtd.2018.01.56

Akasaka, Hiroshi et al. “The Serum Level of KL-6 Is Associated with the Risk of Insulin Resistance and New-onset Diabetes Mellitus: The Tanno-Sobetsu Study.” Internal medicine (Tokyo, Japan) vol. 56,22 (2017): 3009-3018. doi:10.2169/internalmedicine.8716-16

Sokai, Akihiko et al. “Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis.” ERJ open research vol. 3,3 00019-2016. 30 Aug. 2017, doi:10.1183/23120541.00019-2016

Ware, Lorraine B et al. “Derivation and validation of a two-biomarker panel for diagnosis of ARDS in patients with severe traumatic injuries.” Trauma surgery & acute care open vol. 2,1 e000121. 28 Aug. 2017, doi:10.1136/tsaco-2017-000121

Yamakawa, Hideaki et al. “Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.” Journal of thoracic disease vol. 9,2 (2017): 362-371. doi:10.21037/jtd.2017.02.48

Hayakawa, Sho et al. “Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial.” Multidisciplinary respiratory medicine vol. 11 38. 7 Nov. 2016, doi:10.1186/s40248-016-0074-z

Otsuka, Hajime et al. “Clinical features and outcomes of patients with lung cancer as well as combined pulmonary fibrosis and emphysema.” Molecular and clinical oncology vol. 5,3 (2016): 273-278. doi:10.3892/mco.2016.954

Hamai, Kosuke et al. “Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis.” Disease markers vol. 2016 (2016): 4759040. doi:10.1155/2016/4759040

Moazed, Farzad et al. “Cigarette smokers have exaggerated alveolar barrier disruption in response to lipopolysaccharide inhalation.” Thorax vol. 71,12 (2016): 1130-1136. doi:10.1136/thoraxjnl-2015-207886

Hamada, Tsutomu et al. “Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.” BMC pulmonary medicine vol. 15 110. 30 Sep. 2015, doi:10.1186/s12890-015-0105-0

Furukawa, Hiroshi et al. “Autoantibody Profiles in Collagen Disease Patients with Interstitial Lung Disease (ILD): Antibodies to Major Histocompatibility Complex Class I-Related Chain A (MICA) as Markers of ILD.” Biomarker insights vol. 10 63-73. 16 Aug. 2015, doi:10.4137/BMI.S28209

Calfee, Carolyn S et al. “Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies.” Chest vol. 147,6 (2015): 1539-1548. doi:10.1378/chest.14-2454

Nishikiori, Hirotaka et al. “Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis.” BMC pulmonary medicine vol. 14 196. 8 Dec. 2014, doi:10.1186/1471-2466-14-196

Ware, L B et al. “Donor smoking is associated with pulmonary edema, inflammation and epithelial dysfunction in ex vivo human donor lungs.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol. 14,10 (2014): 2295-302. doi:10.1111/ajt.12853

Kakugawa, Tomoyuki et al. “Serum heat shock protein 47 levels are elevated in acute interstitial pneumonia.” BMC pulmonary medicine vol. 14 48. 21 Mar. 2014, doi:10.1186/1471-2466-14-48

Horimasu, Yasushi et al. “Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPD gene polymorphisms.” BMC medical genetics vol. 15 4. 8 Jan. 2014, doi:10.1186/1471-2350-15-4

Ware, Lorraine B et al. “Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome.” Critical care (London, England) vol. 17,5 R253. 24 Oct. 2013, doi:10.1186/cc13080

Aihara, Kensaku et al. “Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis.” PloS one vol. 8,6 e66017. 11 Jun. 2013, doi:10.1371/journal.pone.0066017

Kakugawa, Tomoyuki et al. “Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis.” Cell stress & chaperones vol. 18,5 (2013): 581-90. doi:10.1007/s12192-013-0411-5

Samukawa, Takuya et al. “The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D.” BMC pulmonary medicine vol. 12 55. 11 Sep. 2012, doi:10.1186/1471-2466-12-55

Agrawal, Ashish et al. “Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials.” American journal of physiology. Lung cellular and molecular physiology vol. 303,8 (2012): L634-9. doi:10.1152/ajplung.00195.2012

Shah, Rupal J et al. “A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation vol. 31,9 (2012): 942-9. doi:10.1016/j.healun.2012.05.001

Ilumets, Helen et al. “Ageing and smoking contribute to plasma surfactant proteins and protease imbalance with correlations to airway obstruction.” BMC pulmonary medicine vol. 11 19. 19 Apr. 2011, doi:10.1186/1471-2466-11-19

Sims, Michael W et al. “Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis.” Chest vol. 140,2 (2011): 489-496. doi:10.1378/chest.10-2065

Hisata, Shu et al. “A Normal Range of KL-6/MUC1 Independent of Elevated SP-D Indicates a Better Prognosis in the Patients with Honeycombing on High-Resolution Computed Tomography.” Pulmonary medicine vol. 2011 (2011): 806014. doi:10.1155/2011/806014

Krasnodembskaya, Anna et al. “Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.” Stem cells (Dayton, Ohio) vol. 28,12 (2010): 2229-38. doi:10.1002/stem.544

Fremont, Richard D et al. “Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis.” The Journal of trauma vol. 68,5 (2010): 1121-7. doi:10.1097/TA.0b013e3181c40728

Ware, Lorraine B et al. “Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury.” Chest vol. 137,2 (2010): 288-96. doi:10.1378/chest.09-1484

Shimizu, Yasuo et al. “Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study.” BMC infectious diseases vol. 9 47. 22 Apr. 2009, doi:10.1186/1471-2334-9-47

Inoue, Yoshikazu et al. “Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.” American journal of respiratory and critical care medicine vol. 177,7 (2008): 752-62. doi:10.1164/rccm.200708-1271OC

Heidinger, Kathrin et al. “Polymorphisms in the human surfactant protein-D (SFTPD) gene: strong evidence that serum levels of surfactant protein-D (SP-D) are genetically influenced.” Immunogenetics vol. 57,1-2 (2005): 1-7. doi:10.1007/s00251-005-0775-5

Ishii, H et al. “High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia.” Thorax vol. 58,1 (2003): 52-7. doi:10.1136/thorax.58.1.52

Mukae, H et al. “Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis.” Thorax vol. 57,7 (2002): 623-8. doi:10.1136/thorax.57.7.623

Ilex Life Sciences LLC is an authorized distributor of Yamasa SP-D Kit EIA II.